On April 23, 2025, the Food and Drug Administration sanctioned penpulimab-kcqx (Akeso Biopharma Co., Ltd.) in conjunction with cisplatin or carboplatin and gemcitabine for the initial treatment of peo...
cancer-immunotherapy
Introduction
Chimeric Antigen Receptor (CAR) T-cell therapy has already transformed the landscape of cancer treatment. Now, the 4th generation CAR T-cell therapy, augmented with interleukin-15 (IL-15...
cancer-immunotherapy
cancer-immunotherapy